Retatrutide vs Semaglutide vs Tirzepatide: How They Compare

The fundamental difference between these three medications is how many receptors they target:

Semaglutide is a single-receptor agonist. It activates only GLP-1 receptors, which reduce appetite, slow gastric emptying, and improve blood sugar control. Brands include Ozempic and Wegovy.

Tirzepatide is a dual-receptor agonist. It activates both GLP-1 and GIP receptors. The addition of GIP receptor agonism enhances insulin sensitivity, supports fat metabolism, and may amplify appetite suppression. Brands include Mounjaro and Zepbound.

Retatrutide is a triple-receptor agonist. It activates GLP-1, GIP, and glucagon receptors. The glucagon receptor component increases energy expenditure through thermogenesis and promotes liver fat mobilization. Retatrutide is investigational and has no brand name yet.

Clinical trial data shows a clear pattern: more receptor targets correlate with greater weight loss.

Semaglutide 2.4 mg (STEP 1 trial): approximately 15% body weight loss over 68 weeks.

Tirzepatide 15 mg (SURMOUNT-1 trial): approximately 22.5% body weight loss over 72 weeks.

Retatrutide 12 mg (Phase 2 trial): approximately 24.2% body weight loss over 48 weeks.

Important context: these numbers come from separate trials with different populations and durations. No head-to-head randomized trial has directly compared all three. The retatrutide data is from a smaller Phase 2 study, while semaglutide and tirzepatide numbers come from larger Phase 3 pivotal trials.

Each medication has a different dose range reflecting its pharmacological properties:

Semaglutide: 0.25 mg to 2.4 mg weekly. Escalated over 16-20 weeks. Common compounded vial concentrations: 1-5 mg/mL.

Tirzepatide: 2.5 mg to 15 mg weekly. Escalated over 16-20 weeks. Common compounded vial concentrations: 5-30 mg/mL.

Retatrutide: 1 mg to 12 mg weekly (in clinical trials). Escalated over approximately 12 weeks. Not available in compounded form.

All three are administered as weekly subcutaneous injections. Brand-name versions use prefilled pens; compounded versions (semaglutide and tirzepatide only) are drawn from vials using U-100 insulin syringes.

Semaglutide: FDA-approved. Ozempic approved for type 2 diabetes (2017). Wegovy approved for weight management (2021). Widely available in brand-name pens and compounded vials.

Tirzepatide: FDA-approved. Mounjaro approved for type 2 diabetes (2022). Zepbound approved for weight management (2023). Available in brand-name pens and compounded vials.

Retatrutide: NOT FDA-approved. Currently in Phase 3 clinical trials (as of 2025). Not available through any pharmacy or compounding facility. Potential approval is several years away.

For patients seeking treatment today, semaglutide and tirzepatide are the available options. Retatrutide represents the next generation of GLP-1-class therapy but is not yet accessible outside clinical trials.

All three medications share a common side effect profile driven primarily by their GLP-1 receptor activity. The most frequently reported adverse events are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. These effects are typically most prominent during dose escalation and tend to improve over time.

In clinical trials, the severity and frequency of GI side effects generally increased with higher doses and with the addition of more receptor targets. Retatrutide's glucagon component did not introduce fundamentally new side effects in Phase 2, though the full safety profile will be better understood after Phase 3 completion.

All three medications carry similar warnings regarding potential thyroid C-cell tumor risk (based on animal studies), pancreatitis, and gallbladder-related events. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use GLP-1-class medications.